Postresection CA19-9 and margin status as predictors of recurrence after adjuvant treatment for pancreatic carcinoma: Analysis of NRG oncology RTOG trial 9704

PURPOSE: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predictors of recurrence that may be used to tailor indiv...

Descripción completa

Detalles Bibliográficos
Autores principales: Regine, William F., Winter, Kathryn, Abrams, Ross A., Safran, Howard, Kessel, Ivan L., Chen, Yuhchyau, Fugazzi, James A., Donnelly, Eric D., DiPetrillo, Thomas A., Narayan, Samir, Plastaras, John P., Gaur, Rakesh, Delouya, Guila, Suh, John H., Meyer, Joshua E., Haddock, Michael G., Didolkar, Mukund S., Padula, Gilbert D.A., Johnson, David, Hoffman, John P., Crane, Christopher H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Pancreas Tumor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000159/
https://www.ncbi.nlm.nih.gov/pubmed/29904740
http://dx.doi.org/10.1016/j.adro.2018.01.003

Ejemplares similares

Ejemplares similares